Giant Cell Tumor of the Pelvis: A Systematic Review

22Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This is a systematic review of articles concerning the morbidity, recurrence rate, treatment and treatment complications of pelvic giant cell tumors (GCTs). The key words "giant cell tumor, pelvis" were used to identify articles which included data on patients with pelvic GCTs in English and Chinese databases of published reports from 1949-2012. The articles were filtered by title, abstract and full text. Thirty-eight articles and 165 patients were identified for this review. Data on all identified patients were studies; data in different articles on the same patients was not used repeatedly. The following patient data were collected where possible and subjected to systematic analysis; age, location of GCT, treatment, follow-up, complications, recurrence and whether alive or dead. The mean age of onset was 33.2 years (range, 14-73 years), the peak ages of onset being between 21 and 40 years. A pronounced sex difference was identified, the male:female ratio being 1:1.7. The acetabulum was the commonest area for pelvic GCTs. Forty-eight tumors were primarily located in the iliac, 60 in the acetabular and 31 in the ischiopubic area. Twenty-seven patients experienced complications of treatment. Patients who had been treated by wide resection had the most complications; these included incisional infection and delayed healing of incisions. Local recurrence was common, having occurred in 39/158 patients (24.6%), comprising 24/72 (33.3%) who had undergone intralesional surgery only; 9/20 (45.0%) who had undergone radiotherapy only; 1/51 (2.0%) who had undergone wide resection; and 5/14 patients (35.7%) who had undergone radiation therapy or cryotherapy plus intralesional surgery. Mortality was low (3.2%, 5/158). Pelvic GCT is not common, the acetabular area appears to the most frequent site and the peak age is the third and fourth decades. Although the recurrence rate is high for all pelvic GCTs, the mortality is low. Treatment has a critical influence on recurrence. In spite of the associated complications, the lower local recurrence rate makes wide resection a reasonable option for patients with extensive and/or aggressive GCTs.

References Powered by Scopus

Giant-cell tumor of bone

1000Citations
N/AReaders
Get full text

Giant-cell tumor of bone. An analysis of two hundred and eighteen cases.

597Citations
N/AReaders
Get full text

Resection and reconstruction for primary neoplasms involving the innominate bone

581Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Selective arterial embolization for the treatment of sacral and pelvic giant cell tumor: A systematic review

34Citations
N/AReaders
Get full text

Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection?

27Citations
N/AReaders
Get full text

Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone

21Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Zheng, K., Wang, Z., Wu, S. jia, Ye, Z. ming, Xu, S. feng, Xu, M., … Yu, X. chun. (2015, May 1). Giant Cell Tumor of the Pelvis: A Systematic Review. Orthopaedic Surgery. Sociedade Brasileira de Matematica Aplicada e Computacional. https://doi.org/10.1111/os.12174

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 16

80%

Professor / Associate Prof. 2

10%

Researcher 2

10%

Readers' Discipline

Tooltip

Medicine and Dentistry 14

74%

Social Sciences 3

16%

Chemical Engineering 1

5%

Pharmacology, Toxicology and Pharmaceut... 1

5%

Save time finding and organizing research with Mendeley

Sign up for free